

Advancing Cardiac Ablation

AblaCor™ Medical Corporation has developed the **CircumBlator™ AF Catheter Ablation System** to advance **pulmonary vein isolation (PVI)** ablation procedures for patients with **atrial fibrillation (AFib)**, the most common irregular heart rhythm and a potentially deadly disorder. CircumBlator is designed to overcome drawbacks of current ablation technologies for AFib including “point-by-point” and “balloon” due to their unpredictability in producing durable, continuous, transmural lesions.

♥ Pulmonary Vein Isolation (PVI) is the cornerstone ablation procedure for AFib, but it fails 30% of the time. (Source: *Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation: Karl-Heinz Kuck, M.D., et al. New England Journal of Medicine 2016; 374:2235-2245). The purpose of PVI is to create lesions that achieve complete electrical isolation of the pulmonary veins (PVs). These lesions block irregular signals originating in the PVs from reaching the top chambers of the heart. The fundamental problem with present technologies for achieving successful PVI is maintaining electrode tissue contact for effective isolation of the pulmonary veins. Ablation procedures are known to fail due to poor tissue contact with the ablation catheter around the opening of the PVs. This can result in incomplete ablation, leaving gaps in the lesion. Gaps allow irregular electrical signals to continue to travel from the PVs to the atria, leading to AFib recurrence in about one in three patients.

♥ AblaCor's patent portfolio provides strong protection for the CircumBlator technology. While the CircumBlator System is a platform technology that could be applied to other procedures, AblaCor is focused initially on PVI. The CircumBlator system is designed to provide consistent electrode-tissue contact and stability to achieve durable lesions with minimal AFib recurrence. **Using radiofrequency (RF), the CircumBlator catheter has a novel anchor design, a circumferential electrode array, and feedback-sensing for enhanced lesion creation and verification.** It is protected by a strong portfolio of issued and pending patents.

♥ AblaCor's innovative technology is positioned to access this significant market opportunity. AFib is a healthcare problem for more than **30 million** patients worldwide. AFib is associated with a **five-fold increased risk for stroke**. Hospitalizations for AFib increased 23% between the years 2000 and 2010. The total cost for treating AFib was \$24 billion in the U.S. in 2014. The annual addressable global market for CircumBlator exceeds \$1.2 billion.

♥ AblaCor has a strong, accomplished leadership team. AblaCor is led by **Martin Sklar**, who has guided medical product development teams in early-stage and Fortune 100 companies. His accomplishments have resulted in 20 issued and pending patents and cumulative revenues in excess of \$1 billion. Martin holds a Bachelor of Science degree in Mechanical Engineering from Worcester Polytechnic Institute and a Master of Engineering degree from Dartmouth College.

CONTACTS & KEY INFORMATION

Headquarters	Needham, Massachusetts 02492 USA +1 (781) 248-6841
Website	www.ablacor.com
Investors	Selected private investors
Stage	Seed
Sector	Medical Devices
Platform	CircumBlator™ AF Catheter Ablation System


Mechanism

Novel “single-shot” circumferential ablation method to create continuous lesions designed to achieve complete electrical isolation of the pulmonary veins (PVs).

LEADERSHIP AND ADVISORS

Martin Sklar	Founder, President and Chief Executive Officer
Roy Wallen	Director, Commercialization
Joyce College, RN	Director, Strategic Management
Michael Drues, PhD	Regulatory Affairs Advisor
Jim Bricker	Business Advisor
Robert Flaherty	Business Advisor
Jeremy N. Ruskin, MD	Massachusetts General Hospital, Harvard Medical School; Clinical Advisor
Lawrence S. Rosenthal, MD, PhD	University of Massachusetts (UMass) Memorial Medical Center; Clinical Advisor

CircumBlator™: An innovative catheter to advance pulmonary vein isolation (PVI) for patients with atrial fibrillation (AFib).



Lawrence S. Rosenthal
MD, PhD, FACC, FHRS
Director, Electrophysiology Service;
Professor of Medicine, UMass Memorial Medical Center

“Ablacor’s novel approach of a circular ablator, with its controlled electrode-tissue contact, designed to generate continuous and transmural ablation lesions reliably, holds great promise and would be a major advance.”